NCT06973096View on ClinicalTrials.gov

CART-EGFR-IL13Ra2 in Newly Diagnosed GBM Following Initial Radiotherapy

PHASE1RecruitingINTERVENTIONAL
Enrollment

9

Participants

Timeline

Start Date

July 18, 2025

Primary Completion Date

July 31, 2042

Study Completion Date

July 31, 2042

Conditions
Glioblastoma
Interventions
DRUG

CART-EGFR-IL13Ra2 cells

autologous T cells transduced with a bicistronic lentiviral vector containing a murine scFv targeting EGFR epitope 806 and a humanized scFv targeting IL13Ra2; both scFvs are fused to the 4-1BB and CD3ζ signaling domains.

Trial Locations (1)

19104

RECRUITING

University of Pennsylvania, Philadelphia

All Listed Sponsors
lead

University of Pennsylvania

OTHER

NCT06973096 - CART-EGFR-IL13Ra2 in Newly Diagnosed GBM Following Initial Radiotherapy | Biotech Hunter | Biotech Hunter